Home Biosimilar Antibodies Others Others Sutimlimab (Anti-C1s)
For research use only. Not for use in humans.

Sutimlimab (Anti-C1s)

Synonyms: Complement C1s， C1s protease

Sutimlimab (Anti-C1s) is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. It can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. MW:145.5 KD.

Sutimlimab (Anti-C1s)

Quality Control

Batch: A257901 Purity: 99% Protein concentration: 7.59mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Sutimlimab (Anti-C1s) is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. It can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. MW:145.5 KD.

Product Details

CAS No. 2049079-64-1
Molecular Weight 150 kDa
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05132127 COMPLETED Drug: sutimlimab Cold Agglutinin Disease Sanofi 2021-11-11 PHASE3
NCT03347422 COMPLETED Drug: sutimlimab (BIVV009)|Drug: placebo Cold Agglutinin Disease Bioverativ, a Sanofi company 2018-03-17 PHASE3
NCT03347396 COMPLETED Drug: BIVV009 Agglutinin Disease, Cold Bioverativ, a Sanofi company 2018-03-05 PHASE3

(data from https://clinicaltrials.gov, updated on 2025-09-15)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.